Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 8, 2011, Pages 1263-1272

  Yáñez, Yania ^a   Grau, Elena ^a   Oltra, Silvestre ^a   Cañete, Adela ^a   Martínez, Francisco ^a   Orellana, Carmen ^a   Noguera, Rosa ^b   Palanca, Sarai ^a   Castel, Victoria ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

1p deletion; Minimal residual disease; MYCN; Neuroblastoma; Quantitative reverse transcriptase polymerase chain reaction (QRT PCR)

Indexed keywords

DOUBLECORTIN; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE;

ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER RELAPSE; CANCER STAGING; CHILD; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; NON METASTATIC NEUROBLASTOMA; OVERALL SURVIVAL; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

ADOLESCENT; ADULT; BONE MARROW; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEUROBLASTOMA; NEUROPEPTIDES; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TYROSINE 3-MONOOXYGENASE; YOUNG ADULT;

EID: 79961171204     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-0997-x     Document Type: Article

References (35)

1. IM Ambros J Benard M Boavida N Bown H Caron V Combaret J Couturier C Darnfors O Delattre J Freeman-Edward C Gambini N Gross CM Hattinger A Luegmayr J Lunec T Martinsson K Mazzocco S Navarro R Noguera S O'Neill U Potschger S Rumpler F Speleman GP Tonini A Valent N Van Roy G Amann B De Bernardi P Kogner R Ladenstein J Michon AD Pearson PF Ambros 2003 Quality assessment of genetic markers used for therapy stratification J Clin Oncol 21 11 2077 2084 12775732 10.1200/JCO.2003.03.025 1:STN:280:DC%2BD3s3lt1Srug%3D%3D (Pubitemid 46606355)
2. V Bozionellou D Mavroudis M Perraki, et al. 2004 Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer Clin Cancer Res 10 24 8185 8194 15623593 10.1158/1078-0432.CCR-03-0094 1:CAS:528:DC%2BD2cXhtFGjsrjP (Pubitemid 40053377)
3. GM Brodeur RC Seeger M Schwab HE Varmus JM Bishop 1984 Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage Science 224 1121 1124 6719137 10.1126/science.6719137 1:STN:280: DyaL2c7ps1Chtw%3D%3D (Pubitemid 14106392)
4. GM Brodeur RC Seeger A Barrett F Berthold RP Castleberry G D'Angio B De Bernardi AE Evans M Favrot AI Freeman G Haase O Hartmann FA Hayes L Helson J Kemshead F Lampert J Ninane H Ohkawa T Philip CR Pinkerton J Pritchard T Sawada S Siegel EI Smith Y Tsuchida PA Voute 1988 International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma J Clin Oncol 6 1874 1881 3199170 1:STN:280:DyaL1M%2FmvVSktA%3D%3D (Pubitemid 19089071)
5. Brodeur GM, Maris JM (2002) Neuroblastoma. In: Pizzo PA, Poplack DG (eds) Principles and practice of paediatric oncology, 4th edn. JB. Lippincott Co., Philadelphia, pp 895-938
6. SA Burchill IJ Lewis KR Abrams, et al. 2001 Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year J Clin Oncol 19 1795 1801 11251011 1:CAS:528:DC%2BD3MXisFygsL8%3D (Pubitemid 32230882)
7. O Burgues S Navarro R Noguera A Pellín A Ruiz V Castel A Llombart-Bosch 2006 Prognostic value of the international neuroblastoma pathology classification in neuroblastoma (schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the spanish neuroblastoma registry Virchows Arch 449 4 410 420 16941154 10.1007/s00428-006- 0253-y (Pubitemid 44451315)
8. H Caron 1995 Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma Med Pediatr Oncol 24 215 222 7700165 10.1002/mpo.2950240402 1:STN:280:DyaK2M3hsVGmsw%3D%3D
9. IY Cheung NK Cheung 2001 Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR Clin Cancer Res 7 1698 1705 11410509 1:CAS:528:DC%2BD3MXltV2hs7o%3D (Pubitemid 32708638)
10. NKV Cheung G Heller BH Kushner, et al. 1997 Detection of metastatic neuroblastoma in bone marrow: when is routine histology intensive? J Clin Oncol 15 8 2807 2817 9256123 1:STN:280:DyaK2szpvVWqug%3D%3D (Pubitemid 27330007)
11. H Christiansen F Lampert 1998 Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma Br J Cancer 57 121 126 10.1038/bjc.1988.24
12. SL Cohn AD Pearson WB London T Monclair PF Ambros GM Brodeur A Faldum B Hero T Iehara D Machin V Mosseri T Simon A Garaventa V Castel KK Matthay 2009 The international neuroblastoma risk group (INRG) classification system: an INRG task force report J Clin Oncol 27 289 297 19047291 10.1200/JCO.2008.16.6785
13. MV Corrias LB Faulkner A Pistorio C Rosanda F Callea MS Lo Piccolo P Scaruffi C Marchi L Lacitignola M Occhino C Gambini GP Tonini R Haupt B De Bernardi V Pistoia A Garaventa 2004 Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients Clin Cancer Res 10 7978 7985 15585633 10.1158/1078-0432.CCR-04-0815 1:CAS:528:DC%2BD2cXhtVCrs7rP (Pubitemid 39587539)
14. MV Corrias S Parodi R Haupt L Lacitignola F Negri AR Sementa D Dau F Scuderi B Carlini M Bianchi F Casale L Faulkner A Garaventa 2008 Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma Br J Cancer 98 2 263 269 18182983 10.1038/sj.bjc.6604179 1:STN:280:DC%2BD1c%2Fmt1amsQ%3D%3D (Pubitemid 351161263)
15. + regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop Blood 109 632 642 16985181 10.1182/blood-2006-01-028423 1:CAS:528:DC%2BD2sXivVyrsrc%3D (Pubitemid 46105964)
16. SJ Cotterill AD Pearson J Pritchard AB Foot B Roald JA Kohler J Imeson 2000 Clinical prognostic factors in 1,277 patients with neuroblastoma: results of the European neuroblastoma study group 'survey' 1982-1992 Eur J Cancer 36 901 908 10785596 10.1016/S0959-8049(00)00058-7 1:STN:280:DC%2BD3c3kvFSitg%3D%3D (Pubitemid 30214141)
17. B De Bernardi V Mosseri H Rubie V Castel A Foot R Ladenstein G Laureys M Beck-Popovic A De Lacerda, et al. 2008 Treatment of localised resectable neuroblastoma. results of the LNESG I study by the SIOP Europe neuroblastoma group Br J Cancer 99 1027 1033 18766186 10.1038/sj.bjc.6604640
18. JG Gleeson PT Lin LA Flanagan, et al. 1999 Doublecortin is a microtubuleassociated protein and is expressed widely by migrating neurons Neuron 23 257 271 10399933 10.1016/S0896-6273(00)80778-3 1:CAS:528: DyaK1MXks1Wrsrw%3D (Pubitemid 29315722)
19. LH Lambooy CE Gidding LP van den Heuvel CA Hulsbergen-van de Kaa M Ligtenberg JP Bökkerink RA De Abreu 2003 Real-time analysis of TH gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma Clin Cancer Res 9 812 819 12576454 1:CAS:528:DC%2BD3sXhtVKksbk%3D (Pubitemid 36182619)
20. WB London RP Castleberry KK Matthay AT Look RC Seeger H Shimada P Thorner G Brodeur JM Maris CP Reynolds SL Cohn 2005 Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the children's oncology group J Clin Oncol 23 27 6459 6465 16116153 10.1200/JCO.2005.05.571 1:STN:280:DC%2BD2MvpslKisA%3D%3D (Pubitemid 46190236)
21. AT Look FA Hayes JJ Shuster EC Douglass RP Castleberry LC Bowman EI Smith GM Brodeur 1991 Clinical relevance of tumour cells ploidy and N-myc gene amplification in childhood neuroblastoma: a paediatric oncology group study J Clin Oncol 9 581 591 2066755 1:STN:280:DyaK3M3psVyhtA%3D%3D
22. S Mocellin U Keilholz CR Rossi D Nitti 2006 Circulating tumour cells: the 'leukemic phase' of solid cancers Trends Mol Med 12 130 139 16488189 10.1016/j.molmed.2006.01.006 1:CAS:528:DC%2BD28XisF2gtr0%3D
23. J Moss DG Sanders 1990 Detection of neuroblastoma cells in blood J Clin Oncol 8 736 740 2179482 1:STN:280:DyaK3c7ovVCktA%3D%3D (Pubitemid 20127259)
24. R Noguera A Canete A Pellin A Ruiz M Tasso S Navarro V Castel A Llombart-Bosch 2003 MYCN gain and MYCN amplification in a stage 4S neuroblastoma Cancer Genet Cytogenet 140 2 157 161 12645655 10.1016/S0165-4608(02)00677-5 1:CAS:528:DC%2BD3sXhslKht7Y%3D (Pubitemid 36349017)
25. S Oltra F Martinez C Orellana E Grau JM Fernandez A Canete V Castel 2005 The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma Diagn Mol Pathol 14 1 53 57 15714065 10.1097/01.pas. 0000149876.32376.c0 (Pubitemid 40283863)
26. Perez C, Matthay K, Atkinson J, Seeger R, Shimada H, Haase G, Stram D, Gerbing R, Lukens J (2000) Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 18(1):18-26 (Pubitemid 30036332)
27. CP Reynolds 2004 Detection and treatment of minimal residual disease in high-risk neuroblastoma Pediatr Transplant 8 Suppl 5 56 66 15125707 10.1111/j.1398-2265.2004.00216.x (Pubitemid 38787577)
28. H Rubie B De Bernardi M Gerrard A Canete R Ladenstein J Couturier P Ambros C Munzer AD Pearson A Garaventa P Brock V Castel D Valteau-Couanet K Holmes A Di Cataldo B Brichard V Mosseri C Marquez D Plantaz L Boni J Michon 2011 Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1 J Clin Oncol 29 4 449 455 21172879 10.1200/JCO.2010.29. 5196 1:CAS:528:DC%2BC3MXivFWms7w%3D
29. RC Seeger GM Brodeur H Sather A Dalton SE Siegel KY Wong D Hammond 1985 Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas N Engl J Med 313 1111 1116 4047115 10.1056/NEJM198510313131802 1:STN:280:DyaL28%2FhsValsQ%3D%3D (Pubitemid 16216827)
30. H Shimada IM Ambros LP Dehner J Hata VV Joshi B Roald 1999 Terminology and morphologic criteria of neuroblastic tumors: recommendations by the international neuroblastoma pathology committee Cancer 86 2 349 363 10421272 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.0.CO;2-Y 1:STN:280:DyaK1MzkslKnsg%3D%3D (Pubitemid 29327593)
31. R Spitz B Hero T Simon F Berthold 2006 Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma Clin Cancer Res 12 11 3368 3373 16740759 10.1158/1078-0432.CCR-05- 2495 1:CAS:528:DC%2BD28XltFyis7w%3D
32. S Steen J Nemunaitis T Fisher J Kuhn 2008 Circulating tumor cells in melanoma: a review of the literature and description of a novel technique Bayl Univ Med Cent 21 2 127 132
33. MA Swartz CA Kristensen RJ Melder S Roberge E Calautti D Fukumura, et al. 1999 Cells shed from tumours show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity Br J Cancer 81 756 759 10555742 10.1038/sj.bjc.6690760 1:STN:280:DC%2BD3c%2Fit1Klug%3D%3D (Pubitemid 29504681)
34. C Träger A Vernby A Kullman I Ora P Kogner B Kågedal 2008 mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis Int J Cancer 123 2849 2855 18814238 10.1002/ijc.23846
35. VF Viprey MA Lastowska MV Corrias K Swerts MS Jackson SA Burchill 2008 Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials J Pathol 216 245 252 18702176 10.1002/path.2406 1:CAS:528:DC%2BD1cXht1GqsL7I